Recent Finacing
Recent Raise
AdipoPharma develops PATAS, an adipocyte-targeted insulin sensitizer that restores glucose uptake and lipid biosynthesis to treat insulin resistance in type 2 diabetes, preparing to enter clinical trials.
Focus Areas
Recent Investors
Funding rounds
Investors
See the team members at AdipoPharma.
